Current Opinion in Neurology最新文献

筛选
英文 中文
Isocitrate dehydrogenase-mutant glioma in the post-INDIGO era: advances in classification and management. 后靛蓝时代异柠檬酸脱氢酶突变型胶质瘤:分类和治疗进展。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-12-01 Epub Date: 2026-11-05 DOI: 10.1097/WCO.0000000000001518
Tyler A Lanman
{"title":"Isocitrate dehydrogenase-mutant glioma in the post-INDIGO era: advances in classification and management.","authors":"Tyler A Lanman","doi":"10.1097/WCO.0000000000001518","DOIUrl":"https://doi.org/10.1097/WCO.0000000000001518","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recent advances have reshaped the classification and management of IDH-mutant glioma. Updated molecular diagnostic frameworks, evolving multidisciplinary treatment strategies, and the emergence of mutant IDH inhibitors have introduced new therapeutic opportunities while also raising important unresolved clinical questions. This review summarizes recent developments and ongoing controversies in the post-INDIGO era.</p><p><strong>Recent findings: </strong>Recent cIMPACT-NOW recommendations further refine molecular classification and grading criteria for IDH-mutant glioma. Increasing evidence supports maximal safe resection and, in select cases, supramaximal resection, particularly in astrocytoma. Questions regarding the optimal timing and modality of radiation therapy remain unresolved. Comparative studies of chemotherapy regimens continue to demonstrate tradeoffs between efficacy and toxicity. The INDIGO trial established mutant IDH inhibition as a new treatment paradigm, and ongoing studies seek to optimize patient selection and explore new types of IDH-directed therapies.</p><p><strong>Summary: </strong>Management of IDH-mutant glioma is becoming increasingly individualized and molecularly driven. Although mutant IDH inhibitors represent a major therapeutic advance, their integration with existing treatment paradigms remains uncertain. Ongoing studies will continue to refine prognostic stratification and multidisciplinary management strategies in this population.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":"39 6","pages":"555-563"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roadmap for cognitive neurorehabilitation: challenges and opportunities. 认知神经康复路线图:挑战与机遇。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-12-01 Epub Date: 2026-11-05 DOI: 10.1097/WCO.0000000000001532
Arseny A Sokolov, Philippe Allain, Peggy d'Honincthun, Jean-Michel Pignat, Andrea Serino, Hichem Slama, Kenza Takani, Claire Vallat-Azouvi, Sylvie Willems
{"title":"Roadmap for cognitive neurorehabilitation: challenges and opportunities.","authors":"Arseny A Sokolov, Philippe Allain, Peggy d'Honincthun, Jean-Michel Pignat, Andrea Serino, Hichem Slama, Kenza Takani, Claire Vallat-Azouvi, Sylvie Willems","doi":"10.1097/WCO.0000000000001532","DOIUrl":"https://doi.org/10.1097/WCO.0000000000001532","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cognitive deficits affect 40-50% of patients after acquired brain injury, with a profound impact on participation, work capacity and quality of life. Cognitive neurorehabilitation is a relevant and promising approach to promote cognitive recovery, but the evidence remains limited. This review discusses the clinical state-of-the-art, open questions in clinical research, and outlines a roadmap for future development of this rapidly evolving domain.</p><p><strong>Recent findings: </strong>While optimal contemporary cognitive neurorehabilitation is multimodal and interprofessional, the currently available evidence is diluted by heterogeneous treatment content and patient characteristics, as well as by inadequate methodology and reporting. Several questions remain open: the optimal dose and frequency of therapy, the preferable sequence of treatments, and the factors that moderate treatment effects. We highlight the pressing need for rigorously designed randomized controlled trials (RCTs) with active control conditions, everyday-relevant outcome measures, time by group interaction analyses and long-term follow-up.</p><p><strong>Summary: </strong>Future development of cognitive neurorehabilitation depends on RCTs and single-case experiments using cutting-edge methodology. We propose a roadmap with four tiers: mechanisms and efficacy, assessment of moderating factors, clinical validity as well as consideration of socio-economic impact and implementation from the outset. International collaboration in designing, developing and validating the approaches is warranted to ensure standardization and broad uptake. These efforts will promote the quality and accessibility of cognitive neurorehabilitation.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":"39 6","pages":"504-521"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of seizures in patients with brain tumors. 脑肿瘤患者癫痫发作的处理。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-12-01 Epub Date: 2026-10-20 DOI: 10.1097/WCO.0000000000001523
Hyun Yong Koh, Steven Tobochnik
{"title":"Management of seizures in patients with brain tumors.","authors":"Hyun Yong Koh, Steven Tobochnik","doi":"10.1097/WCO.0000000000001523","DOIUrl":"10.1097/WCO.0000000000001523","url":null,"abstract":"<p><strong>Purpose of review: </strong>Discoveries relating to the cancer neuroscience of gliomas have reframed brain tumor-related epilepsy (BTRE) as the product of reciprocal interactions at the neural-tumor interface. This framework provides the rationale for targeted strategies to optimize both seizure control and brain tumor survival outcomes.</p><p><strong>Recent findings: </strong>Feedforward dynamics involving hyperexcitability and cellular proliferation in glioma-infiltrated cortex drive synaptic remodeling of neural circuits that correlate with shorter survival. Seizure assessment metrics demonstrate that worsening seizure control may precede or align with progressive disease. In this context, early evidence indicates a potential role for targeted tumor-directed therapy in addition to antiseizure medications (ASMs) for optimizing seizure control. Noncontrolled studies evaluating ASM tapering strategies in BTRE suggest that tumor stability is more important for seizure control than the duration of seizure freedom.</p><p><strong>Summary: </strong>BTRE involves dynamic and fluctuating seizure risk driven by tumor biology, tumor-directed therapy, and treatment response. Hyperexcitability at the cellular level and clinical seizure activity are increasingly understood as a reflection of tumor biology and a potentially modifiable target to improve outcomes. The addition of seizure assessments as secondary endpoints in brain tumor clinical trials may lead to a refined individualized and disease-specific approach to ASM management.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":"606-613"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in upper-limb, language and cognitive neurorehabilitation after stroke. 人工智能在中风后上肢、语言和认知神经康复中的应用。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-12-01 Epub Date: 2026-10-26 DOI: 10.1097/WCO.0000000000001530
Annie Hill, Christoph Michael Bauer, Carl Froilan Leochico
{"title":"Artificial intelligence in upper-limb, language and cognitive neurorehabilitation after stroke.","authors":"Annie Hill, Christoph Michael Bauer, Carl Froilan Leochico","doi":"10.1097/WCO.0000000000001530","DOIUrl":"10.1097/WCO.0000000000001530","url":null,"abstract":"<p><strong>Purpose of review: </strong>Artificial intelligence (AI) is being increasingly integrated into upper-limb, language and cognitive neurorehabilitation research and there is interest in where the research currently lies along the pipeline towards clinical implementation and real-world impact.</p><p><strong>Recent findings: </strong>Across these three domains of neurorehabilitation, the research into the use of AI has shown clear potential to enhance assessment, personalize rehabilitation and extend access to care but is yet to demonstrate clinical utility and superiority over other digital rehabilitation approaches. There remain concerns about small and selective datasets being used for modelling, privacy and equity issues and sustainable implementation. It is suggested that AI should be positioned as an important tool in the clinical infrastructure rather than an autonomous clinical decision maker within clinical practice.</p><p><strong>Summary: </strong>Future research across these neurorehabilitation domains should consider implementation risks and needs early in the research pipeline, by using ethical principles and guidelines to ensure transparency and consumer involvement in AI research and implementation into clinical practice.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":"546-552"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FXIa inhibitors and secondary stroke prevention. FXIa抑制剂与继发性脑卒中预防。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-10-27 DOI: 10.1097/WCO.0000000000001520
Lina Palaiodimou, Aikaterini Theodorou, Maria-Ioanna Stefanou, Georgios Tsivgoulis
{"title":"FXIa inhibitors and secondary stroke prevention.","authors":"Lina Palaiodimou, Aikaterini Theodorou, Maria-Ioanna Stefanou, Georgios Tsivgoulis","doi":"10.1097/WCO.0000000000001520","DOIUrl":"https://doi.org/10.1097/WCO.0000000000001520","url":null,"abstract":"<p><strong>Purpose of review: </strong>Patients with noncardioembolic ischemic stroke face a substantial residual risk of recurrence despite antiplatelet therapy, while conventional anticoagulation is unsuitable due to an unacceptably high bleeding risk. Activated factor XI (FXIa) inhibition promises anticoagulant efficacy while sparing hemostasis. We appraise the evidence of FXIa-inhibitors in secondary stroke prevention considering the pivotal OCEANIC-STROKE trial.</p><p><strong>Recent findings: </strong>Phase-2 trials of asundexian and milvexian were reassuring on safety but neutral on imaging-based endpoints, establishing that covert infarcts are a poor surrogate. In the phase-3 OCEANIC-STROKE trial, asundexian added to single or dual antiplatelet therapy reduced recurrent ischemic stroke by 26%, consistently across subtypes, without any excess of major bleeding or intracranial hemorrhage. By contrast, asundexian was inferior to apixaban in atrial fibrillation, a result attributable to dose, comparator, and setting. Consistent with this, the monoclonal antibody abelacimab, which achieves near-complete FXIa-inhibition, reduced bleeding relative to rivaroxaban in atrial fibrillation, though its effect on thromboembolic events has not been established.</p><p><strong>Summary: </strong>FXIa-inhibition is the first anticoagulant strategy preventing recurrent stroke after noncardioembolic ischemic stroke without a bleeding penalty. Confirmation of a class effect from further trials is awaited, alongside questions of duration, deeper inhibition, and use in other cardiovascular indications.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149264043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myotonic dystrophy type 1 - updates on mechanisms of multisystemic manifestations, genetically targeted therapeutics, and preparing for a postapproval world. 1型肌强直性营养不良-多系统表现机制的最新进展,基因靶向治疗,并为批准后的世界做准备。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-10-01 Epub Date: 2026-08-24 DOI: 10.1097/WCO.0000000000001509
Samuel Carrell, Adam D Comer, Nicholas E Johnson
{"title":"Myotonic dystrophy type 1 - updates on mechanisms of multisystemic manifestations, genetically targeted therapeutics, and preparing for a postapproval world.","authors":"Samuel Carrell, Adam D Comer, Nicholas E Johnson","doi":"10.1097/WCO.0000000000001509","DOIUrl":"10.1097/WCO.0000000000001509","url":null,"abstract":"<p><strong>Purpose of review: </strong>Myotonic dystrophy type (DM1) is the most prevalent muscular dystrophy and manifests throughout the lifespan with signs and symptoms in all major organ systems. There are significant updates on therapeutic development and trials focused on muscle disease in DM1, as well as updates on the mechanism and progression of disease in nonmuscle tissues, changes or updates on clinical management, and the societal burden associated with a varied and prevalent disorder.</p><p><strong>Recent findings: </strong>Evidence of improvement with strength and myotonia with genetically targeted treatments in early phase trials. Preparation for natural history studies to evaluate the impact of therapeutics on the heart and central nervous system (CNS), and expansion to early onset forms of DM1. Improvements in our understanding of mechanisms of CNS, cardiac, gastrointestinal, and liver manifestations. Evolving approaches to cardiac monitoring and respiratory care. DM1 is genetically more common than recognized clinically, and how this may affect societal disease burden.</p><p><strong>Summary: </strong>This review highlights genetically targeted therapeutics showing impact for muscle manifestations of DM1, ongoing efforts now shifting to expand to other target tissues and the younger population, and, in preparation for a clinically available medicine, our understanding of societal burden and population genetics of DM1.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":"477-482"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation. 包涵体肌炎的病理机制和治疗的范式转变:在细胞自主肌肉变性和免疫激活的十字路口。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-10-01 Epub Date: 2026-08-24 DOI: 10.1097/WCO.0000000000001511
Naoki Suzuki, Rumiko Izumi, Kensuke Ikeda
{"title":"Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation.","authors":"Naoki Suzuki, Rumiko Izumi, Kensuke Ikeda","doi":"10.1097/WCO.0000000000001511","DOIUrl":"10.1097/WCO.0000000000001511","url":null,"abstract":"<p><strong>Purpose of review: </strong>Inclusion body myositis (IBM) is the most prevalent acquired myopathy in adults over 50 years of age, yet effective disease-modifying therapy has remained elusive. The longstanding debate over whether degeneration or inflammation is the primary driver has now given way to a model of bidirectional interplay. This review critically appraises advances published between January 2025 and June 2026, encompassing molecular pathomechanisms, early diagnostic strategies, disease-modifying therapies, and rehabilitation.</p><p><strong>Recent findings: </strong>A pivotal mechanistic advance is the demonstration that TDP-43 nuclear depletion in IBM myonuclei generates cryptic exon-derived neoantigens that directly activate CD8 + T cells, molecularly unifying cell-autonomous degeneration and adaptive immune activation. In parallel, mitochondrial DNA leakage activates the cGAS-STING innate immune pathway prior to T cell infiltration. An endogenous compensatory mechanism involving the NORAD-Pumilio regulatory axis has also been identified. Clinically, preliminary data from the Phase 2/3 MUSCLE trial suggest a potential 50% slowing of progression in mild-to-moderate IBM with the anti-KLRG1 antibody ulviprubart, pending full peer-reviewed publication, while novel diagnostic and rehabilitation strategies further advance personalized care.</p><p><strong>Summary: </strong>A molecular cascade from cell-autonomous TDP-43 dysfunction to cryptic epitope-driven immune activation could underlie the pathogenesis of IBM. Personalized multidisciplinary care integrating early diagnosis, targeted disease-modifying therapy, and advanced rehabilitation represents the emerging treatment paradigm.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":"461-467"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myopathies in the therapeutic era: measurement as the rate-limiting step. 治疗时代的肌病:测量作为限速步骤。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-10-01 Epub Date: 2026-09-03 DOI: 10.1097/WCO.0000000000001514
Shahram Attarian
{"title":"Myopathies in the therapeutic era: measurement as the rate-limiting step.","authors":"Shahram Attarian","doi":"10.1097/WCO.0000000000001514","DOIUrl":"https://doi.org/10.1097/WCO.0000000000001514","url":null,"abstract":"","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":"39 5","pages":"447-449"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introduction. 编辑介绍。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-10-01 Epub Date: 2026-09-03 DOI: 10.1097/WCO.0000000000001516
{"title":"Editorial introduction.","authors":"","doi":"10.1097/WCO.0000000000001516","DOIUrl":"10.1097/WCO.0000000000001516","url":null,"abstract":"","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":"39 5","pages":"v"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A global comparison of clinical guidelines for the diagnosis and management of migraine: similarities, differences, and gaps. 偏头痛诊断和治疗临床指南的全球比较:相似点、差异和差距。
IF 4.7 2区 医学
Current Opinion in Neurology Pub Date : 2026-10-01 Epub Date: 2026-08-24 DOI: 10.1097/WCO.0000000000001510
Fred Cohen
{"title":"A global comparison of clinical guidelines for the diagnosis and management of migraine: similarities, differences, and gaps.","authors":"Fred Cohen","doi":"10.1097/WCO.0000000000001510","DOIUrl":"10.1097/WCO.0000000000001510","url":null,"abstract":"<p><strong>Purpose of review: </strong>To compare international clinical guidelines for migraine diagnosis and management, identifying consensus, differences, and gaps.</p><p><strong>Recent findings: </strong>Assessed guideline repositories and society websites from 2012 to 2025 for recommendations from American, British, Italian, Japanese, French, and International Headache Society (IHS) guidelines. All guidelines base diagnosis on International Classification of Headache Disorders (ICHD-3) and recommend early acute therapy with analgesics and NSAIDs. Triptans are universally endorsed for moderate-to-severe attacks, while gepants and ditans appear in newer guidelines but remain inaccessible in many countries. Preventive therapy is advised for frequent or disabling attacks; recommended first-line agents include beta-blockers (propranolol), antiseizure medications (ASMs) (topiramate, valproate), and tricyclic antidepressants (amitriptyline). Calcitonin gene-related peptide (CGRP) monoclonal antibodies and gepants are positioned as first-line by American and Japanese guidelines but restricted in Britain and France. OnabotulinumtoxinA is reserved for chronic migraine after several failed oral preventives. Nonpharmacological interventions such as neuromodulation and behavioral therapies are increasingly incorporated. Differences stem primarily from drug availability and insurance coverage. Evidence gaps persist for pediatric, geriatric, and pregnant populations and long-term safety of emerging therapies.</p><p><strong>Summary: </strong>Despite shared principles, migraine guidelines diverge in thresholds and access to newer treatments; global collaboration is needed to address gaps and ensure equitable care. This review provides a global perspective overall.</p>","PeriodicalId":11059,"journal":{"name":"Current Opinion in Neurology","volume":" ","pages":"491-497"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书